Reproducibility of dopamime transporter density measured with 123I-FPCIT SPECT in normal control and Parkinson's disease patients

Annals of Nuclear Medicine

Volumn 18, Issue 7, 2004, Pages 609-616

  Tsuchida, Tatsuro ^a,c,g   Ballinger, James R ^a,c,e   Vines, Douglass ^a,d   Kim, Yun J ^b,c   Utsunomiya, Keita ^a,c,f   Lang, Anthony E ^b,c   Ichise, Masanori ^a,c,d  

^a MOUNT SINAI HOSPITAL   (United States)

^b M/G Shulman Movement Disord Ctr   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^e GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^f OSAKA MEDICAL COLLEGE   (Japan)

^g UNIVERSITY OF FUKUI   (Japan)

Author keywords

Distribution volume ratio; Reproducibility

Indexed keywords

AMANTADINE; BROMOCRIPTINE; CARBIDOPA PLUS LEVODOPA; DOPAMINE TRANSPORTER; IODINE 123; N OMEGA FLUOROPROPYL 2BETA CARBOMETHOXY 3BETA (4 IODOPHENYL)NORTROPANE; NORTROPANE DERIVATIVE; PERGOLIDE MESILATE; ROPINIROLE; SELEGILINE; TOLCAPONE; UNCLASSIFIED DRUG; 2 CARBOMETHOXY 8 (3 FLUOROPROPYL) 3 (4 IODOPHENYL)TROPANE; 2-CARBOMETHOXY-8-(3-FLUOROPROPYL)-3-(4-IODOPHENYL)TROPANE; CARRIER PROTEIN; DIAGNOSTIC AGENT; MEMBRANE PROTEIN; NERVE PROTEIN; RADIOPHARMACEUTICAL AGENT; TROPANE DERIVATIVE;

ADULT; AGED; ARTICLE; CALCULATION; CLINICAL ARTICLE; CONTROLLED STUDY; DENSITY; DOPAMINE RELEASE; EVALUATION; FEMALE; HUMAN; MALE; PARKINSON DISEASE; PRIORITY JOURNAL; RELIABILITY; REPRODUCIBILITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; STATISTICAL SIGNIFICANCE; TISSUE SPECIFICITY; TREATMENT OUTCOME; BRAIN; CLINICAL TRIAL; COMPARATIVE STUDY; COMPUTER ASSISTED DIAGNOSIS; CONTROLLED CLINICAL TRIAL; METABOLISM; METHODOLOGY; MIDDLE AGED; REFERENCE VALUE; SCINTISCANNING; SENSITIVITY AND SPECIFICITY; TISSUE DISTRIBUTION;

ADULT; AGED; BRAIN; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; FEMALE; HUMANS; IMAGE INTERPRETATION, COMPUTER-ASSISTED; MALE; MEMBRANE GLYCOPROTEINS; MEMBRANE TRANSPORT PROTEINS; MIDDLE AGED; NERVE TISSUE PROTEINS; PARKINSON DISEASE; RADIOPHARMACEUTICALS; REFERENCE VALUES; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TISSUE DISTRIBUTION; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TROPANES;

EID: 10044244641     PISSN: 09147187     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02984583     Document Type: Article

References (36)

1. Leenders KL, Salmon EP, Tyrrell P, Perani D, Brooks DJ, Sager H, et al. The nigrostriatal dopaminergic system assessed in vivo by positron emission tomography in healthy volunteer subjects and patients with Parkinson's disease. Arch Neurol 1990; 47: 1290-1298.
2. Innis RB, Seibyl JP, Scanley BE, Laruelle M, Abi-Dargham A, Wallece E, et al. Single photon emission computed tomographic imaging demonstrates loss of striatal dopamine transporters in Parkinson disease. Proc Natl Acad Sci USA 1993; 90: 11965-11969.
3. 11C-WIN 35,428 reveals marked declines in mild Parkinson's disease. Ann Neurol 1993; 34: 423-431.
4. 11C]RTI-32 PET studies of the dopamine transporters in early dopa-naive Parkinson's disease: implications for the symptomatic threshold. Neurology 1997; 48: 1578-1583.
5. 123I]β-CIT binding kinetics in human brain. J Neurol Transm [GenSect] 1993; 94: 137-146.
6. 123I]β- CIT striatal uptake correlates with symptom severity in Parkinson's disease. Ann Neurol 1995; 38: 589-598.
7. 123I]FP-CIT SPECT shows a pronounced decline of striatal dopamine transporter labelling in early and advanced Parkinson's disease. J Neurol Neurosurg Psychiatry 1997; 62: 133-140.
8. 123I]FP-CIT SPET in the demonstration of the dopaminergic deficit in Parkinson's disease. Eur J Nucl Med 1997; 24: 68-71.
9. 123I]β-CIT binding to dopamine transporters in healthy human subjects. J Cereb Blood Flow Metab 1994; 14: 982-994.
10. Neumeyer JL, Wang S, Gao Y, Milius RA, Kula NS, Campbell A, et al. N-ω-fluoroalkyl analogs of (1R)-2β-carbomethoxy-3β-(4- iodophenyl)-tropane (β-CIT): radiotracers for positron emission tomography and single photon emission computed tomography imaging of dopamine transporters. J Med Chem 1994; 37: 1558-1561.
11. Abi-Dargham A, Gandelman MS, DeErausquin GA, Zea-Ponce Y, Zoghbi SS, Baldwin RM, et al. SPECT imaging of transporters in human brain with iodine-123-fluoroalkyl analogs of β-CIT. J Nucl Med 1996; 37: 1129-1133.
12. Scheffel U, Lever JR, Abraham P, Parham KR, Mathews WB, Kopajtic T, et al. N-substituted phenyltropanes as in vivo binding ligands for rapid imaging studies of the dopamine transporter. Synapse 1997; 25: 345-349.
13. Kuikka JT, Bergström KA, Ahonen A, Hiltunen J, Haukka J, Lansimies E, et al. Comparison of iodine-123 labelled 2β-carbomethoxy-3β-(4- iodophenyl)tropane and 2β-carbomethoxy-3β-(4-iodophenyl)-N-(3- fluoropropyl) nortropane for imaging of the dopamine transporter in the living human brain. Eur J Nucl Med 1995; 22: 356-360.
14. 123I]FPCIT SPECT. J Nucl Med 1999; 40: 753-761.
15. Volkow ND, Fowler JS, Wang GJ, Dewey SL, Schlyer D, MacGregor R, et al. Reproducibility of repeated measures of carbon-11-raclopride binding in the human brain. J Nucl Med 1993; 34: 609-613.
16. Vingerhoets FJG, Snow BJ, Schulzer M, Morrison S, Ruth TJ, Holden JE, et al. Reproducibility of fluorine-18-6-fluorodopa positron emission tomography in normal human subjects. J Nucl Med 1994; 35: 18-24.
17. Vingerhoets FJG, Schulzer M, Ruth TJ, Holden JE, Snow BJ. Reproducibility and discriminating ability of fluorine-18-6-fluoro-L-dopa PET in Parkinson's disease. J Nucl Med 1996; 37: 421-426.
18. Seibyl JP, Laruelle M, van Dyck CH, Wallace E, Baldwin RM, Zoghbi S, et al. Reproducibility of iodine-123-β-CIT SPECT brain measurement of dopamine transporters. J Nucl Med 1996; 37: 222-228.
19. Ichise M, Ballinger JR, Vines D, Tsai S, Kung HF. Simplified quantification and reproducibility studies of dopamine D2-receptor binding with iodine-123-IBF SPECT in healthy subjects. J Nucl Med 1997; 38: 31-37.
20. Hoehn MM, Yahr MD. Parkinsonism: onset, progression, and mortality. Neurology 1967; 17: 427-442.
21. Lang AE, Fahn S. Assessment of Parkinson's disease. In: Munsat TL, ed. Quantification of Neurologic Deficit. Boston; Butterworths, 1989: 285-309.
22. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinicopathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992; 55: 181-184.
23. Zea-Ponce Y, Baldwin RM, Laruelle M, Wang S, Neumeyer JL, Innis RB. Simplified multidose preparation of iodine-123-β-CIT: a marker for dopamine transporters. J Nucl Med 1995; 36: 525-529.
24. Vines DC, Ivo BD, Ballinger JR, Ichise M. External radioactive reference markers in SPECT imaging of the dopamine system. J Nucl Med Technol 1999; 27: 112-116.
25. Snedecor GW, Cochran WG. Specific indices of interater reliability. In: Snedecor GW, Cochran WG, eds. Statistical Methods, 6th ed. Ames, IO; Iowa State University Press, 1989: 147-156.
26. Booij J, Habraken JBA, Bergmans P, Tissingh G, Winogrodzka A, Wolters EC, et al. Imaging of dopamine transporters with iodine-123-FP-CIT SPECT in healthy controls and patients with Parkinson's disease. J Nucl Med 1998; 39: 1879-1884.
27. 18F-dopa uptake in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy. Ann Neurol 1990; 28: 547-555.
28. Gibb WR. Neuropathology of Parkinson's disease and related syndromes. Neurol Clin 1992; 10: 361-376.
29. Kish SJ, Shannak K, Hornykiewicz O. Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease: pathophysiologic and clinical implications. N Engl J Med 1988; 318: 876-880.
30. Ishikawa T, Dhawan V, Kazumata K, Chaly T, Mandel F, Meumeyer J, et al. Comparative nigrostriatal dopaminergic imaging with iodine-123-βCIT-FP/ SPECT and fluorine-18-FDOPA/PET. J Nucl Med 1996; 37: 1760-1765.
31. Seibyl JP, Marek K, Sheff K, Zoghbi S, Baldwin RM, Chamey DS, et al. Iodine-123-β-CIT and iodine-123-FPCIT SPECT measurement of dopamine transporters in healthy subjects and Parkinson's patients. J Nucl Med 1998; 39: 1500-1508.
32. Tissingh G, Booij J, Bergmans P, Winogrodzka A, Janssen AGM, van Royen EA, et al. Iodine-123-N-ω-fluoropropyl-2β-carbomethoxy-3β-(4- iodophenyl)tropane SPECT in healthy controls and early-stage, drug-naive Parkinson's disease. J Nucl Med 1998; 39: 1143-1148.
33. 123I]β-CIT/SPECT imaging demonstrates bilateral loss of dopamine transporters in hemi-Parkinson's disease. Neurology 1996; 46: 231-237.
34. Vingerhoets FJG, Snow BJ, Lee CS, Schulzer M, Mak E, Calne DB. Longitudinal fluorodopa positron emission tomographic studies of the evolution of idiopathic parkinsonism. Ann Neurol 1994; 36: 759-764.
35. 18F]dopa-PET and clinical study of the rate of progression in Parkinson's disease. Brain 1996; 119: 585-591.
36. Ichise M, Ballinger JR, Golan H, Vines D, Luong A, Tsai S, Kung HF. Noninvasive quantification of dopamine D2 receptors with iodine-123-IBF SPECT. J Nucl Med 1996; 37: 13-520.